Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 163

1.

Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases.

Kanai O, Fujita K, Okamura M, Nakatani K, Mio T.

Ann Oncol. 2016 Mar 31. pii: mdw148. [Epub ahead of print] No abstract available.

PMID:
27037297
2.

Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.

Kanai O, Fujita K, Nakatani K, Mio T.

Respirol Case Rep. 2016 Jan 14;4(1):28-31. doi: 10.1002/rcr2.145. eCollection 2016 Mar.

3.

Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema.

Fujita K, Kim YH, Nakatani K, Mio T.

Clin Case Rep. 2015 Oct;3(10):875-8. doi: 10.1002/ccr3.371. Epub 2015 Sep 7.

4.

Patient with lung adenocarcinoma manifesting as an unusual migratory pulmonary infiltration.

Fujita K, Shim J, Nakatani K, Mio T.

BMJ Case Rep. 2015 Jul 31;2015. pii: bcr2015211771. doi: 10.1136/bcr-2015-211771. No abstract available.

PMID:
26231190
5.

Hypereosinophilic obliterative bronchiolitis clinically mimicking diffuse panbronchiolitis: four-year follow-up.

Kobayashi T, Inoue H, Mio T.

Intern Med. 2015;54(9):1091-4. doi: 10.2169/internalmedicine.54.3767. Epub 2015 May 1.

6.

The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.

Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Sakata K, Sase H, Isobe T, Morikami K, Shindoh H, Mio T, Ebiike H, Taka N, Aoki Y, Ishii N.

Mol Cancer Ther. 2014 Nov;13(11):2547-58. doi: 10.1158/1535-7163.MCT-14-0248. Epub 2014 Aug 28.

7.

Invasive pulmonary aspergillosis in a patient presenting with idiopathic systemic capillary leak syndrome.

Hayama M, Shime N, Mio T.

BMJ Case Rep. 2014 May 23;2014. pii: bcr2014203764. doi: 10.1136/bcr-2014-203764.

PMID:
24859554
8.

Massive haemoptysis following dabigatran administration in a patient with bronchiectasis.

Hayama M, Inoue H, Wada H, Mio T.

BMJ Case Rep. 2014 Feb 19;2014. pii: bcr2013201001. doi: 10.1136/bcr-2013-201001.

9.

[A case of lung paragonimiasis superinfection with hookworm presenting difficulty in discrimination].

Minezaki S, Hirama T, Shiono A, Masumoto A, Mio T, Utsugi H, Uchida Y, Kaga A, Hagiwara K, Kanazawa M.

Kansenshogaku Zasshi. 2013 Nov;87(6):756-60. Japanese.

PMID:
24483024
10.

[Case report; a case of lung and skin nocardiosis in a non-immunocompromised patient].

Masumoto A, Hirama T, Kawana H, Kawashima A, Shiono A, Mio T, Nagata M, Hagiwara K, Kanazawa M.

Nihon Naika Gakkai Zasshi. 2013 Oct 10;102(10):2679-81. Japanese. No abstract available.

PMID:
24400549
11.

[A case of postoperative thymic carcinoma recurrence that was effectively treated with combination chemotherapy of nedaplatin and docetaxel].

Kataoka Y, Okamoto K, Kitamura T, Hayama M, Tanaka H, Kanai O, Kobayashi T, Okamura M, Inoue H, Oshio M, Motoishi M, Mio T, Sawai S, Hanaoka J.

Gan To Kagaku Ryoho. 2013 Dec;40(13):2561-3. Review. Japanese.

PMID:
24335370
12.

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.

Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.

Cancer Sci. 2013 Oct;104(10):1346-52. doi: 10.1111/cas.12237. Epub 2013 Aug 20.

13.

Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.

Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T, Terada T, Teramukai S, Mishima M, Inui K, Katsura T.

Clin Pharmacokinet. 2013 Jul;52(7):593-609. doi: 10.1007/s40262-013-0058-5.

PMID:
23532985
14.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators.

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

15.

Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.

Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.

Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30.

PMID:
22752216
16.

Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial.

Fujita S, Katakami N, Masago K, Yoshioka H, Tomii K, Kaneda T, Hirabayashi M, Kunimasa K, Morizane T, Mio T.

BMC Cancer. 2012 May 21;12:185. doi: 10.1186/1471-2407-12-185.

17.

Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.

Nagai H, Yasuda H, Hatachi Y, Xue D, Sasaki T, Yamaya M, Sakamori Y, Togashi Y, Masago K, Ito I, Kim YH, Mio T, Mishima M.

Int J Oncol. 2012 Jul;41(1):24-30. doi: 10.3892/ijo.2012.1461. Epub 2012 May 2.

PMID:
22552400
18.

A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.

Okishio K, Mio T, Kawahara M, Yoshioka H, Yanagihara K, Daimon T, Furuse K.

Jpn J Clin Oncol. 2012 May;42(5):387-93. doi: 10.1093/jjco/hys028. Epub 2012 Mar 19.

19.

Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.

Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T, Mishima M.

Clin Lung Cancer. 2012 Sep;13(5):385-90. doi: 10.1016/j.cllc.2011.11.009. Epub 2012 Jan 28.

PMID:
22285568
20.

A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.

Kawahara M, Kubo A, Komuta K, Fujita Y, Sasaki Y, Fukushima M, Daimon T, Furuse K, Mishima M, Mio T.

J Thorac Oncol. 2012 Dec;7(12):1845-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk